Karolina Palucka

Karolina Palucka has been a leader in translating dendritic cell biology into clinical cancer vaccine therapies, developing next-generation DC vaccine approaches that incorporate tumor neoantigens, optimized maturation cocktails, and combination with checkpoint inhibitors. Her clinical trials have demonstrated that DC vaccines can generate measurable anti-tumor T cell responses and clinical benefit in melanoma and breast cancer. She has advanced DC vaccine manufacturing processes for clinical-grade production. Her translational work bridges fundamental DC biology and clinical immunotherapy.